Cohort study observes improved CRT response in CRT nonresponders, suggesting potential clinical benefits of vericiguat.
In this small cohort of CRT nonresponders, vericiguat increased CRT response at 1 year, likely through improved mitochondrial function and reduced inflammatory/oxidative stress. Larger studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Sardu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: